Jennison Associates
SLXP

Jennison Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Jennison Associates’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-477,205
Closed -$54.9M – 791
2014
Q4 		$54.9M Buy
+477,205
New +$57.8M 0.05% 311

Other funds holding SLXP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates's SLXP Position: Q1 2015 in Review

Jennison Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 477,205 shares — an estimated $54.9M sold.

Jennison Associates first reported a position in SLXP in Q4 2014 and held it in 1 quarter. The position peaked at $54.9M in Q4 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Jennison Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Jennison Associates sold 477,205 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $54.9M.
  • Jennison Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2014 and held it in 1 quarter.
  • Jennison Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $54.9M in Q4 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Jennison Associates's 13F filing for Q1 2015, filed 4 May 2015.